title: PPARγ as a therapeutic target in cystic fibrosis.
abstract: Cystic fibrosis (CF) is characterized by a proinflammatory pulmonary condition that may result from increased infections and altered intracellular metabolism in CFTR-deficient cells. The lipid-activated transcription factor peroxisome proliferator-activated receptor-γ (PPARγ) has well-established roles in immune cell function and inflammatory modulation and has been demonstrated to play an important role in the heightened inflammatory response in CF cells. Here, we summarize current literature describing PPARγ-dependent alterations of CF cells and discuss the potential of PPARγ ligands for treating CF.
authors.affiliation: Department of Pediatric Pulmonology, University Medical Center Utrecht, Utrecht, The Netherlands.
authors.forename: Johanna F
authors.initials: JF
authors.lastname: Dekkers
authors.forename: Cornelis K
authors.initials: CK
authors.lastname: van der Ent
authors.forename: Eric
authors.initials: E
authors.lastname: Kalkhoven
authors.forename: Jeffrey M
authors.initials: JM
authors.lastname: Beekman
mesh_terms: D000818:Animals; D003550:Cystic Fibrosis / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000235:genetics / Q000378:metabolism; D006801:Humans; D047495:PPAR gamma / Q000819:agonists* / Q000378:metabolism
chemical_list: D047495:PPAR gamma; D019005:Cystic Fibrosis Transmembrane Conductance Regulator